ID   KHYG-1
AC   CVCL_2976
SY   KHYG1; KHYG
DR   EFO; EFO_0022649
DR   ArrayExpress; E-MTAB-7721
DR   ArrayExpress; E-MTAB-7722
DR   cancercelllines; CVCL_2976
DR   Cell_Model_Passport; SIDM01661
DR   Cosmic; 1534877
DR   Cosmic; 1542070
DR   Cosmic; 2025323
DR   Cosmic; 2390214
DR   Cosmic; 2785203
DR   DepMap; ACH-001100
DR   DSMZ; ACC-725
DR   DSMZCellDive; ACC-725
DR   FANTOM5_SSTAR; 10777-110G3
DR   GEO; GSM472000
DR   IARC_TP53; 13193
DR   JCRB; JCRB0156
DR   JCRB; NIHS0226
DR   Lonza; 733
DR   Wikidata; Q54899912
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RX   PubMed=10803505;
RX   PubMed=10803526;
RX   PubMed=16827800;
RX   PubMed=19194464;
RX   PubMed=21052088;
RX   PubMed=25586472;
RX   PubMed=31160637;
WW   Info; Wikipedia; -; https://en.wikipedia.org/wiki/KHYG-1
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: LL-100 blood cancer cell line panel.
CC   Population: Japanese.
CC   Characteristics: IL2 dependent.
CC   Doubling time: 24-48 hours (PubMed=10803526); ~30-40 hours (DSMZ=ACC-725); ~54 hours (Note=Lot 11012010), ~30 hours (Note=Lots 07242006 and 11202015), ~25 hours (Note=Lot 10182016) (JCRB=JCRB0156).
CC   HLA typing: A*11:01:01,24:02:01; B*35:01:01,54:01:01; C*01:02:01,03:03:01; DPA1*02:01:01,02:01:01; DPB1*19:01,14:01:01; DQA1*01:03:01,01:03:01; DRA*01:01:01,01:02:02; DRB1*08:03:02,11:01:01 (DSMZCellDive=ACC-725).
CC   Sequence variation: Mutation; HGNC; HGNC:6407; KRAS; Simple; p.Gly12Ala (c.35G>C); ClinVar=VCV000045122; Zygosity=Unspecified (DepMap=ACH-001100).
CC   Sequence variation: Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg248Trp (c.742C>T); ClinVar=VCV000012347; Zygosity=Unspecified (PubMed=10803526; DepMap=ACH-001100).
CC   Omics: Genomics; Whole exome sequencing.
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Discontinued: JCRB; NIHS0226; true.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
ST   Source(s): DSMZ=ACC-725; JCRB=JCRB0156
ST   Amelogenin: X
ST   CSF1PO: 12
ST   D13S317: 9,13
ST   D16S539: 9
ST   D18S51: 13,18
ST   D19S433: 13,14
ST   D21S11: 30,32.2
ST   D2S1338: 17,19
ST   D3S1358: 15,16
ST   D5S818: 9,11
ST   D7S820: 10,11
ST   D8S1179: 13
ST   FGA: 21,24
ST   Penta D: 11,13
ST   Penta E: 5
ST   TH01: 6
ST   TPOX: 9,11
ST   vWA: 17
DI   NCIt; C82217; Natural killer cell lymphoblastic leukemia/lymphoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Female
AG   45Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 30
//
RX   DOI=10.1016/B978-0-12-221970-2.50457-5;
RA   Drexler H.G.;
RT   "The leukemia-lymphoma cell line factsbook.";
RL   (In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001).
//
RX   PubMed=10803505; DOI=10.1038/sj.leu.2401778;
RA   Drexler H.G., Matsuo Y.;
RT   "Malignant hematopoietic cell lines: in vitro models for the study of
RT   natural killer cell leukemia-lymphoma.";
RL   Leukemia 14:777-782(2000).
//
RX   PubMed=10803526; DOI=10.1038/sj.leu.2401769;
RA   Yagita M., Huang C.-L., Umehara H., Matsuo Y., Tabata R., Miyake M.,
RA   Konaka Y., Takatsuki K.;
RT   "A novel natural killer cell line (KHYG-1) from a patient with
RT   aggressive natural killer cell leukemia carrying a p53 point
RT   mutation.";
RL   Leukemia 14:922-930(2000).
//
RX   PubMed=16827800; DOI=10.1111/j.1349-7006.2006.00226.x; PMCID=PMC11159954;
RA   Liu A., Takakuwa T., Luo W.-J., Fujita S., Aozasa K.;
RT   "Alterations in ATR in nasal NK/T-cell lymphoma and chronic active
RT   Epstein-Barr virus infection.";
RL   Cancer Sci. 97:605-610(2006).
//
RX   PubMed=19194464; DOI=10.1038/leu.2009.3;
RA   Iqbal J., Kucuk C., Deleeuw R.J., Srivastava G., Tam W., Geng H.-M.,
RA   Klinkebiel D.L., Christman J.K., Patel K.N., Cao K., Shen L., Dybkaer K.,
RA   Tsui I.F.L., Ali H.H., Shimizu N., Au W.Y., Lam W.L., Chan W.-C.;
RT   "Genomic analyses reveal global functional alterations that promote
RT   tumor growth and novel tumor suppressor genes in natural killer-cell
RT   malignancies.";
RL   Leukemia 23:1139-1151(2009).
//
RX   PubMed=21052088; DOI=10.1038/leu.2010.255;
RA   Iqbal J., Weisenburger D.D., Chowdhury A., Tsai M.-Y., Srivastava G.,
RA   Greiner T.C., Kucuk C., Deffenbacher K.E., Vose J.M., Smith L., Au W.Y.,
RA   Nakamura S., Seto M., Delabie J., Berger F., Loong F., Ko Y.-H.,
RA   Sng I., Liu X., Loughran T.P. Jr., Armitage J.O., Chan W.-C.;
RT   "Natural killer cell lymphoma shares strikingly similar molecular
RT   features with a group of non-hepatosplenic gammadelta T-cell lymphoma
RT   and is highly sensitive to a novel aurora kinase A inhibitor in
RT   vitro.";
RG   International Peripheral T-cell Lymphoma Project;
RL   Leukemia 25:348-358(2011).
//
RX   PubMed=25586472; DOI=10.1038/ncomms7025; PMCID=PMC7743911;
RA   Kucuk C., Jiang B., Hu X.-Z., Zhang W.-Y., Chan J.K.C., Xiao W.-M.,
RA   Lack N., Alkan C., Williams J.C., Avery K.N., Kavak P., Scuto A.,
RA   Sen E., Gaulard P., Staudt L.M., Iqbal J., Zhang W.-W., Cornish A.,
RA   Gong Q., Yang Q.-P., Sun H., d'Amore F.A., Leppa S., Liu W.-P., Fu K.,
RA   de Leval L., McKeithan T.W., Chan W.-C.;
RT   "Activating mutations of STAT5B and STAT3 in lymphomas derived from
RT   gammadelta-T or NK cells.";
RL   Nat. Commun. 6:6025.1-6025.12(2015).
//
RX   PubMed=31160637; DOI=10.1038/s41598-019-44491-x; PMCID=PMC6547646;
RA   Quentmeier H., Pommerenke C., Dirks W.G., Eberth S., Koeppel M.,
RA   MacLeod R.A.F., Nagel S., Steube K.G., Uphoff C.C., Drexler H.G.;
RT   "The LL-100 panel: 100 cell lines for blood cancer studies.";
RL   Sci. Rep. 9:8218.1-8218.14(2019).
//